$-1.13
(Market cap
$1,805 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
65
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.4
-
Debt to Equity
-1.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
50,785,785
10 Years Aggregate
CFO
€-238.85 Mln
EBITDA
€-293.05 Mln
Net Profit
€-332.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
| 55.7 | -30.1 | 8.8 | 573.4 | 91.4 | 18.4 | -- |
|
BSE Sensex*
| -9.0 | 2.4 | 2.0 | -5.8 | 6.7 | 8.0 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
| 705.6 | -60.3 | 98.4 | -54.7 | -50.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nanobiotix (NBTX)
|
36.0 | 1,804.9 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 |
| 23.8 | 12,015.6 | 19,358.3 | 944.7 | 9.6 | 5.5 | 11.9 | 0.8 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 1.8 | 165.3 | 2.8 | -49.2 | -86.4 | 764.8 | -- | 20.1 | |
| 3.6 | 804.5 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 5.4 | 507.8 | 156.3 | -138.0 | -16.7 | -121.5 | -- | 5.8 |
Shareholding Pattern
View DetailsAbout Nanobiotix (NBTX)
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline... hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. Read more
-
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
-
Co-Founder, President of the Executive Board & CEO
Mr. Laurent Levy Ph.D.
-
Headquarters
Paris
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nanobiotix (NBTX)
What is the current share price of Nanobiotix (NBTX) Today?
The share price of Nanobiotix (NBTX) is $35.99 (NASDAQ) as of 16-Jun-2026 16:00 EDT. Nanobiotix (NBTX) has given a return of 91.44% in the last 3 years.
What is the current PB & PE ratio of Nanobiotix (NBTX)?
Since, TTM earnings of Nanobiotix (NBTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Nanobiotix (NBTX)?
The 52-week high and low of Nanobiotix (NBTX) are Rs 57.14 and Rs 4.18 as of 17-Jun-2026.
What is the market cap of Nanobiotix (NBTX)?
Nanobiotix (NBTX) has a market capitalisation of $ 1,805 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nanobiotix (NBTX)?
Before investing in Nanobiotix (NBTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.